In addition, it is recommended that the duration of future clinical trials of GLP-1RAs for AD extend to 2 to 3 years to evaluate long-term outcomes, including changes in cognition, activities of daily living, instrumental activities of daily living, and biomarkers for tau and A
Safety and Precautions This section summarizes known safety signals from clinical research
Dietary reassessment forms the cornerstone of breaking through a weight loss plateau
Monitoring is especially crucial for repeat recipients and anyone beginning treatment with predisposing health factors
People should realize that these are long-term drugs, he said
Vermont Avenue, Los Angeles, CA, 90029